secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rapport Therapeutics, Inc. (RAPP)
CIK:        0002012593
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093321
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rapport Therapeutics Q2 net loss $18.1M; cash $336.1M; IPO raised $174.4M gross
-------------------------------------------------------------------------------

- Net loss $18.1M vs $6.4M YoY; R&D expense $15.7M vs $4.7M YoY.
- Cash, cash equivalents and short-term investments $336.1M, expected to fund operations through end of 2026.
- IPO with concurrent private placement raised $174.4M gross ($157.6M net).
- Phase 2a trial of RAP-219 in focal epilepsy on track for Q3 2024 initiation; topline data mid-2025.
- Board member Terry-Ann Burrell to transition off board after Form 10-Q filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2012593/000095017024093321/0000950170-24-093321-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2012593/000095017024093321/rapp-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093321

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer